Active	Status	Sponsor type	Region	Phase	Filter
8 Active 5 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lilienfeld-Toal, Marie von
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial) Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial) Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial) Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Data readout from DREAMM-8 trial in combination with pomalidomide and dexamethasone for 2L+ multiple myeloma Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jan 2021 - Dec 2021 : Initiation of DREAMM-10 trial for 1L transplant ineligible multiple myeloma in combination with novel agent Dec 2020 - Dec 2020 : Data from DREAMM-8 trial for multiple myeloma at ASH 2020 More	Recruiting	3	357	Europe, Japan, US, RoW	Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib	GlaxoSmithKline	Multiple Myeloma	01/24	05/29
Heine, Annkristin
NCT05414162: Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy	Recruiting	N/A	60	Europe	Cardiac MRI	University Hospital, Bonn	DLBCL, Multiple Myeloma, Cytokine Release Syndrome, Myocarditis, CAR T-cell Therapy, ALL, PCBCL, Follicular Lymphoma, MCL	05/24	12/25
Pflugmacher, Robert
NCT06270173: Post-Market Study of The Tripod-Fix Vertebral Body Augmentation System in Osteoporotic Vertebral Compression Fractures	Recruiting	N/A	50	Europe	Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)	Wiltrom Co., Ltd., Maxis Medical GmbH	Osteoporotic Vertebral Compression Fractures	07/25	12/25
SOFTBONE, NCT05676320: Investigating Bone Cement With or Without Inossiaâ„¢ Cement Softener for Vertebral Compression Fractures	Recruiting	N/A	150	Europe, Canada	V-Flex, Kyphoplasty, V-Steady	Inossia AB, EIT Health, Uppsala University	Vertebral Compression Fracture	12/24	12/25
Strauß, Andreas
NCT04795921: Investigating the Sleeping Habits of Patients With Haemophilia	Recruiting	N/A	208	Europe		University Hospital, Bonn, University of Wuppertal	Sleep Disorder, Psychological, Activity, Motor	03/22	03/22
NCT04550988: Sonography and Haemophilia	Recruiting	N/A	5	Europe	feasibility study	University Hospital, Bonn, Swedish Orphan Biovitrum	Sonography, Haemophilia	07/22	12/22
NCT04524481: Osteoporosis and Haemophilia	Recruiting	N/A	250	Europe		PD Dr. Andreas Strauß, Bayer	Osteoporosis, Haemophilia, Bone Mass	02/23	03/23
IPO, NCT05132348: Immunophenotyping in Patients With Osteoporosis	Recruiting	N/A	250	Europe	Immunological markers	University Hospital, Bonn	Immunophenotyping Blood Samples of Patients With Osteoporosis	02/26	10/26